The Selective mGlu5 Receptor Agonist CHPG Inhibits Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats and Modulates the Binding Characteristics of Dopamine D2 Receptors in the Rat Striatum Interactions with Adenosine A2a Receptors

被引:0
作者
Patrizia Popoli
Antonella Pèzzola
Maria Torvinen
Rosaria Reggio
Annita Pintor
Laura Scarchilli
Kjell Fuxe
Sergi Ferrè
机构
[1] Istituto Superiore di Sanita`,Department of Pharmacology
[2] Viale Regina Elena 299,Division of Cellular and Molecular Neurochemistry, Department of Neuroscience
[3] Karolinska Institute,undefined
来源
Neuropsychopharmacology | 2001年 / 25卷
关键词
Metabotropic glutamate (mGlu) receptors; Adenosine A; receptors; Dopamine D; receptors; CHPG; Striatum; Parkinson's disease;
D O I
暂无
中图分类号
学科分类号
摘要
In 6-hydroxydopamine-lesioned rats, the selective mGlu5 receptor agonist (RS)-2-Cholro-5-Hydroxyphenylglycine (CHPG, 1-6 μg/10 μl intracerebroventricularly) significantly inhibited contralateral turning induced by quinpirole and, to a lesser extent, that induced by SKF 38393. The inhibitory effects of CHPG on quinpirole-induced turning were significantly potentiated by an adenosine A2A receptor agonist (CGS 21680, 0.2 mg/kg IP) and attenuated by an A2A receptor antagonist (SCH 58261, 1 mg/kg IP). In rat striatal membranes, CHPG (100–1,000 nM) significantly reduced the affinity of the high-affinity state of D2 receptors for the agonist, an effect potentiated by CGS 21680 (30 nM). These results show the occurrence of functional interactions among mGlu5, adenosine A2A, and dopamine D2 receptors in the regulation of striatal functioning, and suggest that mGlu5 receptors may be regarded as alternative/integrative targets for the development of therapeutic strategies in the treatment of Parkinson's disease.
引用
收藏
页码:505 / 513
页数:8
相关论文
共 153 条
  • [1] Albin RL(1989)The functional anatomy of basal ganglia disorders Trends Neurosci 12 366-375
  • [2] Young AB(1990)Functional architecture and basal ganglia circuits: neural substrates of parallel processing Trends Neurosci 13 266-271
  • [3] Penney JB(1999)Group I mGlu receptor modulation of dopamine release in the rat striatum in vivo Eur J Pharmacol 369 175-181
  • [4] Alexander GR(1996)The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia TINS 19 19-24
  • [5] Crutcher MD(1999)Metabotropic glutamate receptors and cell-type-specific vulnerability in the striatum: implication for ischemia and Huntington's disease Exp Neurol 158 97-108
  • [6] Bruton RK(1990)Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease TINS 13 272-276
  • [7] Ge J(1999)Striatal A NeuroReport 10 687-691
  • [8] Barnes NM(1997) receptors differentially regulate spontaneous and K Neuropharmacology 36 265-267
  • [9] Calabresi P(1991)-evoked glutamate release in vivo in young and aged rats Proc Natl Acad Sci USA 88 7238-7241
  • [10] Pisani A(1993)(RS)-2-cholro-5-hydroxyphenylglycine (CHPG) activates mGlu J Neurosci 13 5402-5406